High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection

详细信息    查看全文

• 作者：Fred Poordad ; Charles S. Landis ; Armen Asatryan ; Daniel F. Jackson III ; Teresa I. Ng ; Bo Fu ; Chih-Wei Lin ; Betty Yao and Jens Kort
• 刊名：Liver International
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：36
• 期：8
• 页码：1125-1132
• 全文大小：281K
• ISSN：1478-3231

文摘

ABT-530 is a next-generation hepatitis C virus (HCV) NS5A inhibitor with potent pangenotypic antiviral activity in vitro. Paritaprevir is an NS3/4A protease inhibitor codosed with ritonavir that displays in vitro activity against HCV genotypes 1–4 and 6.